SCM Lifescience
Latest round
- Series C
Last raised
- Sep 2018
Total raised
- $49M
Investors
- 18
About SCM Lifescience
Founded in 2014 and based in Incheon, South Korea, SCM Lifescience operates as a biotechnology company that develops stem cell isolation and stem cell production technology for patients with immunological conditions such as graft-versus-host disease(GVHD), atopic dermatitis, acute pancreatitis, diabetes, and asthma.8 million shares at KRW 17,000 per share on the KOSDAQ.
Who invested in SCM Lifescience
18 investors across 3 rounds
See all investors in SCM Lifescience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SCM Lifescience
Who invested in SCM Lifescience?
SCM Lifescience has 18 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SCM Lifescience raised?
SCM Lifescience has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did SCM Lifescience last raise money?
SCM Lifescience's most recent round on record is a Series C, in Sep 2018.
What does SCM Lifescience do?
Founded in 2014 and based in Incheon, South Korea, SCM Lifescience operates as a biotechnology company that develops stem cell isolation and stem cell production technology for patients with immunological conditions such as graft-versus-host disease(GVHD), atopic dermatitis, acute pancreatitis, diabetes, and asthma.
Where is SCM Lifescience headquartered?
SCM Lifescience is headquartered in Incheon, South Korea.
Which VCs invest in companies like SCM Lifescience?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at SCM Lifescience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like SCM Lifescience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.